Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 28.05 -1.41% -0.40
PTLA closed down 1.41 percent on Monday, November 11, 2019, on 77 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical PTLA trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Inside Day Range Contraction 0.00%
MACD Bearish Signal Line Cross Bearish -1.41%
Hammer Candlestick Bullish -1.41%
Calm After Storm Range Contraction -1.41%
20 DMA Resistance Bearish -1.16%
50 DMA Resistance Bearish -1.16%
Calm After Storm Range Contraction -1.16%
Inside Day Range Contraction -1.16%
Bearish Engulfing Bearish -1.44%

Older signals for PTLA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Clinical Medicine Surgery Inflammation Seattle Genetics Spinal Muscular Atrophy Inflammatory Disorders Thrombosis Astellas Pharma Anticoagulants Factor X Hematologic Disorders Portola Pharmaceuticals
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.95
52 Week Low 14.81
Average Volume 771,662
200-Day Moving Average 29.735
50-Day Moving Average 28.531
20-Day Moving Average 28.8308
10-Day Moving Average 29.345
Average True Range 1.1159
ADX 22.08
+DI 14.8332
-DI 24.1854
Chandelier Exit (Long, 3 ATRs ) 27.9023
Chandelier Exit (Short, 3 ATRs ) 29.6577
Upper Bollinger Band 30.8302
Lower Bollinger Band 26.8314
Percent B (%b) 0.3
BandWidth 13.869889
MACD Line 0.215
MACD Signal Line 0.3488
MACD Histogram -0.1338
Fundamentals Value
Market Cap 1.62 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -6.16
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.30
Resistance 3 (R3) 29.31 28.90 29.09
Resistance 2 (R2) 28.90 28.59 28.90 29.02
Resistance 1 (R1) 28.48 28.39 28.28 28.47 28.95
Pivot Point 28.07 28.07 27.97 28.07 28.07
Support 1 (S1) 27.65 27.76 27.45 27.64 27.15
Support 2 (S2) 27.24 27.56 27.24 27.08
Support 3 (S3) 26.82 27.24 27.01
Support 4 (S4) 26.81